Review



bcl2l1 small  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology bcl2l1 small
    Figure 4. miR‑133a negatively regulates <t>Bcl2l1</t> expression. A total of 48 h post‑transfection, miR‑133a and Bcl2l1 expression were detected using reverse transcription‑quantitative polymerase chain reaction and western blot analysis. (A) miR‑133a expression; (B) Bcl2l1 mRNA expression; (C) Bcl2l1 protein expression. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA: HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; siRNA, small interfering RNA.
    Bcl2l1 Small, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcl2l1+small/pm30320356-55-41-48?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 19 article reviews
    bcl2l1 small - by Bioz Stars, 2026-07
    93/100 stars

    Images

    1) Product Images from "Abnormal expression of miR‑133a in patients with acute myocardial infarction following radical surgery for gastric cancer and the underlying mechanism."

    Article Title: Abnormal expression of miR‑133a in patients with acute myocardial infarction following radical surgery for gastric cancer and the underlying mechanism.

    Journal: Molecular medicine reports

    doi: 10.3892/mmr.2018.9541

    Figure 4. miR‑133a negatively regulates Bcl2l1 expression. A total of 48 h post‑transfection, miR‑133a and Bcl2l1 expression were detected using reverse transcription‑quantitative polymerase chain reaction and western blot analysis. (A) miR‑133a expression; (B) Bcl2l1 mRNA expression; (C) Bcl2l1 protein expression. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA: HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; siRNA, small interfering RNA.
    Figure Legend Snippet: Figure 4. miR‑133a negatively regulates Bcl2l1 expression. A total of 48 h post‑transfection, miR‑133a and Bcl2l1 expression were detected using reverse transcription‑quantitative polymerase chain reaction and western blot analysis. (A) miR‑133a expression; (B) Bcl2l1 mRNA expression; (C) Bcl2l1 protein expression. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA: HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; siRNA, small interfering RNA.

    Techniques Used: Expressing, Polymerase Chain Reaction, Western Blot, Transfection, Standard Deviation, Negative Control, Small Interfering RNA

    Figure 5. Effects of miR‑133a on HUVEC proliferation. A total of 48 h post‑transfection, HUVEC proliferation was determined by MTT assay. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA, HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; siRNA, small interfering RNA.
    Figure Legend Snippet: Figure 5. Effects of miR‑133a on HUVEC proliferation. A total of 48 h post‑transfection, HUVEC proliferation was determined by MTT assay. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA, HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; siRNA, small interfering RNA.

    Techniques Used: MTT Assay, Transfection, Standard Deviation, Negative Control, Small Interfering RNA

    Figure 3. Bcl2l1 is a direct target of miR‑133a. (A) Interaction between miR‑133a and the 3'UTR of Bcl2l1 was predicted using TargetScan. (B) LUC activity of a reporter containing Bcl2l1‑WT 3'UTR or Bcl2l1‑MUT 3'. Bcl2l1‑MUT indicates the Bcl2l1 3'UTR with a mutation in the miR‑133a binding site. All data are presented as the mean ± standard deviation of three independent experiments. *P<0.05 vs. the control group. Bcl2l1, B‑cell lymphoma 2‑like 1; LUC, luciferase; miR‑133a, microRNA‑133a; MUT, mutant; UTR, untranslated region; WT, wild type.
    Figure Legend Snippet: Figure 3. Bcl2l1 is a direct target of miR‑133a. (A) Interaction between miR‑133a and the 3'UTR of Bcl2l1 was predicted using TargetScan. (B) LUC activity of a reporter containing Bcl2l1‑WT 3'UTR or Bcl2l1‑MUT 3'. Bcl2l1‑MUT indicates the Bcl2l1 3'UTR with a mutation in the miR‑133a binding site. All data are presented as the mean ± standard deviation of three independent experiments. *P<0.05 vs. the control group. Bcl2l1, B‑cell lymphoma 2‑like 1; LUC, luciferase; miR‑133a, microRNA‑133a; MUT, mutant; UTR, untranslated region; WT, wild type.

    Techniques Used: Activity Assay, Mutagenesis, Binding Assay, Standard Deviation, Control, Luciferase

    Figure 6. Effects of miR‑133a on HUVEC apoptosis. (A) A total of 48 h post‑transfection, HUVEC apoptosis was determined by flow cytometry. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA, HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. (B) Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; FITC, fluorescein isothiocyanate; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; PI, propidium iodide; siRNA, small interfering RNA.
    Figure Legend Snippet: Figure 6. Effects of miR‑133a on HUVEC apoptosis. (A) A total of 48 h post‑transfection, HUVEC apoptosis was determined by flow cytometry. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA, HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. (B) Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; FITC, fluorescein isothiocyanate; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; PI, propidium iodide; siRNA, small interfering RNA.

    Techniques Used: Flow Cytometry, Transfection, Standard Deviation, Negative Control, Small Interfering RNA



    Similar Products

    bcl2l1 small  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology bcl2l1 small
    Figure 4. miR‑133a negatively regulates <t>Bcl2l1</t> expression. A total of 48 h post‑transfection, miR‑133a and Bcl2l1 expression were detected using reverse transcription‑quantitative polymerase chain reaction and western blot analysis. (A) miR‑133a expression; (B) Bcl2l1 mRNA expression; (C) Bcl2l1 protein expression. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA: HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; siRNA, small interfering RNA.
    Bcl2l1 Small, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcl2l1+small/pm30320356-55-41-48?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 1 article reviews
    bcl2l1 small - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 4. miR‑133a negatively regulates Bcl2l1 expression. A total of 48 h post‑transfection, miR‑133a and Bcl2l1 expression were detected using reverse transcription‑quantitative polymerase chain reaction and western blot analysis. (A) miR‑133a expression; (B) Bcl2l1 mRNA expression; (C) Bcl2l1 protein expression. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA: HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; siRNA, small interfering RNA.

    Journal: Molecular medicine reports

    Article Title: Abnormal expression of miR‑133a in patients with acute myocardial infarction following radical surgery for gastric cancer and the underlying mechanism.

    doi: 10.3892/mmr.2018.9541

    Figure Lengend Snippet: Figure 4. miR‑133a negatively regulates Bcl2l1 expression. A total of 48 h post‑transfection, miR‑133a and Bcl2l1 expression were detected using reverse transcription‑quantitative polymerase chain reaction and western blot analysis. (A) miR‑133a expression; (B) Bcl2l1 mRNA expression; (C) Bcl2l1 protein expression. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA: HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; siRNA, small interfering RNA.

    Article Snippet: A miR-133a inhibitor (5'CAG CUG GUU GAA GGG GAC CAA A3'; 100 nM), NC (sense, 5'UUC UCC GAA CGU GUC ACG UTT3' and antisense, 5'ACG UGA CAC GUU CGG AGA ATT3'; 50 nM) or 2 μl B-cell lymphoma 2 (Bcl-2)-like 1 (Bcl2l1) small interfering (si)RNA (cat. no. sc-43630; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) were transfected into HUVECs (5x104 cells/well) using the Lipofectamine® LTX kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

    Techniques: Expressing, Polymerase Chain Reaction, Western Blot, Transfection, Standard Deviation, Negative Control, Small Interfering RNA

    Figure 5. Effects of miR‑133a on HUVEC proliferation. A total of 48 h post‑transfection, HUVEC proliferation was determined by MTT assay. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA, HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; siRNA, small interfering RNA.

    Journal: Molecular medicine reports

    Article Title: Abnormal expression of miR‑133a in patients with acute myocardial infarction following radical surgery for gastric cancer and the underlying mechanism.

    doi: 10.3892/mmr.2018.9541

    Figure Lengend Snippet: Figure 5. Effects of miR‑133a on HUVEC proliferation. A total of 48 h post‑transfection, HUVEC proliferation was determined by MTT assay. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA, HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; siRNA, small interfering RNA.

    Article Snippet: A miR-133a inhibitor (5'CAG CUG GUU GAA GGG GAC CAA A3'; 100 nM), NC (sense, 5'UUC UCC GAA CGU GUC ACG UTT3' and antisense, 5'ACG UGA CAC GUU CGG AGA ATT3'; 50 nM) or 2 μl B-cell lymphoma 2 (Bcl-2)-like 1 (Bcl2l1) small interfering (si)RNA (cat. no. sc-43630; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) were transfected into HUVECs (5x104 cells/well) using the Lipofectamine® LTX kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

    Techniques: MTT Assay, Transfection, Standard Deviation, Negative Control, Small Interfering RNA

    Figure 3. Bcl2l1 is a direct target of miR‑133a. (A) Interaction between miR‑133a and the 3'UTR of Bcl2l1 was predicted using TargetScan. (B) LUC activity of a reporter containing Bcl2l1‑WT 3'UTR or Bcl2l1‑MUT 3'. Bcl2l1‑MUT indicates the Bcl2l1 3'UTR with a mutation in the miR‑133a binding site. All data are presented as the mean ± standard deviation of three independent experiments. *P<0.05 vs. the control group. Bcl2l1, B‑cell lymphoma 2‑like 1; LUC, luciferase; miR‑133a, microRNA‑133a; MUT, mutant; UTR, untranslated region; WT, wild type.

    Journal: Molecular medicine reports

    Article Title: Abnormal expression of miR‑133a in patients with acute myocardial infarction following radical surgery for gastric cancer and the underlying mechanism.

    doi: 10.3892/mmr.2018.9541

    Figure Lengend Snippet: Figure 3. Bcl2l1 is a direct target of miR‑133a. (A) Interaction between miR‑133a and the 3'UTR of Bcl2l1 was predicted using TargetScan. (B) LUC activity of a reporter containing Bcl2l1‑WT 3'UTR or Bcl2l1‑MUT 3'. Bcl2l1‑MUT indicates the Bcl2l1 3'UTR with a mutation in the miR‑133a binding site. All data are presented as the mean ± standard deviation of three independent experiments. *P<0.05 vs. the control group. Bcl2l1, B‑cell lymphoma 2‑like 1; LUC, luciferase; miR‑133a, microRNA‑133a; MUT, mutant; UTR, untranslated region; WT, wild type.

    Article Snippet: A miR-133a inhibitor (5'CAG CUG GUU GAA GGG GAC CAA A3'; 100 nM), NC (sense, 5'UUC UCC GAA CGU GUC ACG UTT3' and antisense, 5'ACG UGA CAC GUU CGG AGA ATT3'; 50 nM) or 2 μl B-cell lymphoma 2 (Bcl-2)-like 1 (Bcl2l1) small interfering (si)RNA (cat. no. sc-43630; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) were transfected into HUVECs (5x104 cells/well) using the Lipofectamine® LTX kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

    Techniques: Activity Assay, Mutagenesis, Binding Assay, Standard Deviation, Control, Luciferase

    Figure 6. Effects of miR‑133a on HUVEC apoptosis. (A) A total of 48 h post‑transfection, HUVEC apoptosis was determined by flow cytometry. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA, HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. (B) Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; FITC, fluorescein isothiocyanate; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; PI, propidium iodide; siRNA, small interfering RNA.

    Journal: Molecular medicine reports

    Article Title: Abnormal expression of miR‑133a in patients with acute myocardial infarction following radical surgery for gastric cancer and the underlying mechanism.

    doi: 10.3892/mmr.2018.9541

    Figure Lengend Snippet: Figure 6. Effects of miR‑133a on HUVEC apoptosis. (A) A total of 48 h post‑transfection, HUVEC apoptosis was determined by flow cytometry. Con, untreated HUVECs; NC: HUVECs transfected with NC; inhibitor, HUVECs transfected with a miR‑133a inhibitor; inhibitor + Bcl2l1 siRNA, HUVECs cotransfected with a miR‑133a inhibitor and Bcll12 siRNA. (B) Data are presented as the mean ± standard deviation. *P<0.05 vs. the Con group; #P<0.05 vs. the NC group; &P<0.05 vs. the inhibitor group. Bcl2l1, B‑cell lymphoma 2‑like 1; FITC, fluorescein isothiocyanate; HUVECs, human umbilical vein endothelial cells; miR‑133a, microRNA‑133a; NC, negative control; PI, propidium iodide; siRNA, small interfering RNA.

    Article Snippet: A miR-133a inhibitor (5'CAG CUG GUU GAA GGG GAC CAA A3'; 100 nM), NC (sense, 5'UUC UCC GAA CGU GUC ACG UTT3' and antisense, 5'ACG UGA CAC GUU CGG AGA ATT3'; 50 nM) or 2 μl B-cell lymphoma 2 (Bcl-2)-like 1 (Bcl2l1) small interfering (si)RNA (cat. no. sc-43630; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) were transfected into HUVECs (5x104 cells/well) using the Lipofectamine® LTX kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

    Techniques: Flow Cytometry, Transfection, Standard Deviation, Negative Control, Small Interfering RNA